In order to characterize pneumococcal endovascular infection in the post-vaccination era, a retrospective nationwide study based on the Israeli Adult IPD database was conducted. Between 2010 and 2019, 0.6% (23 cases) of IPD cases were of endovascular type, occurring mainly in males (72.3%) with underlying medical conditions (78.2%). Additional pneumococcal source (10 patients) and concomitant infections were not uncommon. Penicillin and ceftriaxone susceptibility rates were 65.2% and 91.3%, respectively; 60.9% of the isolates were not covered by the pneumococcal conjugate vaccine. 21.7% of patients died during hospitalization. In conclusion, pneumococcal endovascular infections still carry significant morbidity and mortality.
|Original language||American English|
|Number of pages||6|
|Journal||European Journal of Clinical Microbiology and Infectious Diseases|
|State||Published - Nov 2022|
Bibliographical noteFunding Information:
We greatly acknowledge Ronit Trefler for serotyping, and Efrat Steinberger and Etti Kreiff for their assistance in data collection and management. The IAIPD study principal investigator was Gili Regev-Yochay and the IsraNIP Project principal investigator was Ron Dagan. Additional members of the IAIPD group who contributed: Marc Assous, Yonit Wiener-Well (Shaare Zedek Medical Center, Jerusalem, Israel); Haim Ben-Zvi, Hila Shaked, Jihad Bishara (Rabin Medical Center, Petah Tikva, Israel); Rita Bardenstein, Oren Zimchony (Kaplan Medical Center, Rehovot, Israel); Larissa Brik, Ariella Levkovich, Miriam Weinberger (Assaf Harofeh Medical Center, Tzrifin, Israel); Bibiana Chazan, Yoram Kennes (HaEmek Medical Center, Afula, Israel); Michal Chowers, Yosi Paitan (Meir Medical Center, Kfar Saba, Israel); Ronit Cohen-Poradosu, Talia Finn, Yael Paran, David Schwartz, Michal Katzir (Tel Aviv Medical Center, Tel Aviv, Israel); Alicia Embon, Yevgenia Tziba (Barzilai Medical Center, Ashkelon, Israel); Sarit Freimann, Valery Istomin (Hillell Yaffe Medical Center, Hadera, Israel); Yuval Geffen, Renato Finkelstein, Ilana Oren (Rambam Medical Center, Haifa, Israel); Danny Glikman, Shifra Sela (Western Galilee Hospital, Nahariya, Israel); Mirit Hershman, Israel Potasman, Itzhak Srugo (Bnai Zion Medical Center, Haifa); Gill Smollan, Galia Rahav (Sheba Medical Center, Ramat Gan, Israel); Camellia Khoury-Assi (French Hospital, Nazareth, Israel); Mandelbaum Sari, Regev Cohen (Laniado Hospital–Sanz Medical Center, Netanya, Israel); Yasmin Maor, Orna Schwartz, Michal Stein (Edith Wolfson Medical Center, Holon, Israel); Danny Miron, Hagai Rechnitzer (Ziv Medical Center, Safed, Israel); Nehama Peled, Nurit Porat, Klaris Reisenberg (Soroka University Medical Center, Beersheba, Israel); Pninit Shaked-Mishan, Gabriel Weber (Carmel Medical Center, Haifa); Yehudit Sheindler (Maayanei Hayeshua Hospital, Bnei Brak, Israel); Hiba Abu Zaid (Peoria Medical Center, Tiberias, Israel); Jacob Strahilevitz, Violetta Temper (Hadassah-Hebrew University, Jerusalem); Olga Sverdlob (Maccabi Healthcare Services, Rehovot).
The IAIPD is part of the IsraNIP project. This study was supported in part by Wyeth (Pfizer), manufacturer of Prevnar 7 and Prevnar 13 [grant no. 0887Z1-4603]. Wyeth (Pfizer) had no role in designing the study, collecting the data, analyzing the data, interpreting the data, writing the report, or in the decision to submit the paper for publication.
© 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
- Endovascular infections
- Infective endocarditis
- Invasive pneumococcal disease